Skip to main content

Highlights

  1. 1
    Brain communications · 2023
    PMID: 37188222PMCID: PMC10176239DOIFirst author52 citations
  2. 2
    Journal of Alzheimer's disease reports · 2024
    PMID: 38405348PMCID: PMC10894616DOISenior author24 citations
  3. 3
    AJNR. American journal of neuroradiology · 2023
    PMID: 37321857PMCID: PMC10337614DOIFirst author17 citations

Publications

110 publications

Active

13 grants
  • PI
    Understanding Psychosis Heterogeneity In Late Life (UPHILL)
    National Institute on Aging · 2026–2031
    R01AG096446-01A1
  • PI
    Circulating Antibody Repertoire And Blood-Brain-Barrier Impairment to explain NEuRopsychiatric symptoms of "invisible" brain injury
    U.S. Department of Defense · 2025–2029
    HT9425-25-1-0789
  • Co-I
    Prism-PET/EMMT: High resolution, cost effective, portable, and upright brain PET scanner for early diagnosis of Alzheimer's disease
    National Institute on Aging · 2024–2029
    U01AG082845-01A1
  • MPI
    Tau progression index (TPI): An individualized predictor of Alzheimer's Disease trajectory based on subject-specific connectomes
    National Institute on Aging · 2024–2029
    R01AG085972-01A1
  • MPI
    Brain fluid clearance and misfolded protein dynamics following traumatic brain injury
    National Institute on Aging · 2023–2029
    R01AG077576-03
  • Co-I
    Quantitative MRI-based cerebral oxygen metabolism in Alzheimer's disease
    National Institute on Aging · 2023–2028
    R01AG080011-04
  • PI
    Chemokine Receptor Inhibition for Alzheimer's Disease
    William H. Donner Foundation · 2024–2027
    WHDF 243779-01
  • MPI
    Understanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's Disease
    National Institute on Aging · 2021–2027 · via Columbia University· 2 renewals
    R01AG072753-05
  • Co-I
    Anatomy of the circle of Willis, cerebral blood flow, and Alzheimer's disease biomarkers in hypertension
    National Heart, Lung, and Blood Institute · 2022–2027
    R01HL 111724-09
  • PI
    Leronlimab in Alzheimer's Disease
    William H. Donner Foundation · 2025–2027
    WDF 255568-01
  • PI
    The LUCINDA Trial
    National Institute on Aging · 2019–2026
    R01AG057681-02
  • KP
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
    S10OD034271-01
  • KP
    Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
    National Institute on Aging · 2020–2026
    R01AG063846-01A1
Completed grants (10)
  • Co-I
    CSF Clearance in Sporadic Alzheimer's Disease
    National Institute on Aging · 2019–2025
    R01AG057848-02
  • Co-I
    Hypertension, brain clearance and markers of neurodegeneration
    National Institute of Neurological Disorders and Stroke · 2019–2025
    R01NS104364-02
  • KP
    7T Magnetic Resonance Imaging System for Basic, Translational and Clinical Research
    Office of the Director, NIH · 2021–2025
    S10OD027039-01A1
  • Co-I
    Functional Connectivity Network in default mode regions provides the underlying infrastructure for task-based functional co-de/activation networks
    National Institute on Aging · 2020–2024
    R01AG057962-03
  • PI
    CSF clearance and brain amyloid dynamics after traumatic brain injury
    National Institute of Neurological Disorders and Stroke · 2019–2023
    R56NS111052-01
  • KP
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
    S10OD030447-01
  • Co-I
    CSF Clearance with 11C-Butanol PET Predicts Amyloid Deposition
    National Institute on Aging · 2020–2022
    R56AG058913-02
  • Co-I
    PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
    National Institute on Aging · 2019–2022
    RF1AG057570-02
  • Co-I
    Understanding the dynamic interactions between tau pathology and microglia-mediated inflammation in Alzheimer's Disease
    National Institute on Aging · 2019–2021
    R56AG064873-01
  • PI
    Imaging inflammation in focal epilepsy
    NINDS · 2008–2015 · via NIH RePORTER
    K23NS057579-06

Clinical research

7 studies

Active

5 studies
  • PI
    Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease
    PHASE2 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
    Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease; Alzheimer's Disease
    NCT07553338
  • PI
    UPHILL: Understanding Psychosis Heterogeneity in Late Life
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
  • PI
    Imaging biodistribution of 11C PK11195 using PET
    New York University School of Medicine · OPEN TO ACCRUAL (as of 2021)
  • PI
    Multimodal neuroimaging in traumatic brain injury
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
  • PI
    Understanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's Disease
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (2)
  • PI
    The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
    PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
    Alzheimer Disease; Mild Cognitive Impairment
    NCT03649724
  • PI
    New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Care
    American College of Radiology · IRB STUDY CLOSURE (as of 2023)
    Alzheimer's Disease; Dementia; Mild Cognitive Impairment
    NCT04426539

External relationships

Other

Stryder Corp. d/b/a Handshake